Form 4: Rocket Pharmaceuticals Director Gotham Makker Acquires Stock Options

Director Gotham Makker acquired stock options in Rocket Pharmaceuticals, exercisable for 26,604 shares of common stock.

Summary

• On June 13, 2024, Gotham Makker, a director of Rocket Pharmaceuticals, acquired stock options to purchase shares of the company's common stock.
• Makker acquired options for 23,944 shares at an exercise price of $22.86, which will vest on June 13, 2025.
• Additionally, Makker acquired options for 2,660 shares at an exercise price of $22.86, also vesting on June 13, 2025; these options were issued in lieu of $40,000 in director retainer fees.
• Following these transactions, Makker directly holds options exercisable for 26,604 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of stock options by a director is generally a good sign, but it's a routine transaction.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
• The acceptance of stock options in lieu of cash retainer fees demonstrates a commitment to the company's long-term success.

Future Outlook

The document does not contain specific forward-looking statements, but the acquisition of stock options suggests an expectation of future value appreciation.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company directors and officers, which can be informative for investors.

Stakeholder Impact

• The acquisition of stock options by a director could positively influence shareholder sentiment.

Key Dates